2018 Speakers:

Gaby Anthonijs, Early Development and Alliance Suppliers Strategy Lead I BRQC Janssen Quality Planning & Strategy,  Janssen Pharmaceutical


Gaby Anthonijs brings over 30 years of pharmaceutical experience as she began her career at Solvay as a Scientific Associate (CRA) and subsequently held global management positions at Glaxo, Astra Pharmaceutica, Janssen Pharmaceutica, Yamanouchi Europe, Medtronic (medical devices), Farma Research, MSource, Astellas and Johnson & Johnson. She served as the VP/General Manager at a full-service CRO in the Netherlands with a 40-bed Phase I unit. Gaby received a Bachelor of Medicine and her M.Sc. from the Free University Amsterdam in Medical Sciences.


Gaby Anthonijs re-joined Janssen Pharmaceutical Companies of Johnson & Johnson in November 2011 whereby she was globally responsible to develop and establish an E2E Vendor Lifecycle Management strategy, process and oversight including Performance Management of the various vendors (or vendor types) through mutually agreed Key Performance Indicators (“metrics”) as well as issue capturing, tracking, resolution and escalation. Since Jan. 2014, Gaby Anthonijs is in the position of CRO Q&C Liaison, responsible for ensuring effective harmonization, central coordination, implementation and maintenance of activities associated with Quality & Compliance oversight associated with global CRO vendors to ensure Inspection Readiness.  Since Nov. 2016, Gaby Anthonijs is in the position of Alliance Suppliers Strategy lead, Strategic Sourcing Network Quality Lead at BioResearch Quality & Compliance Janssen (BRQC) Janssen Quality Planning & Strategy. In May 2017 she was asked to also take the responsibilities of Early Development ESP Oversight as a Lead.

Dr Dorothy Bray, CEO, ImmunoClin


Dr Dorothy Bray is a Senior Executive and Entrepreneur in biopharmaceutical industry with over 25 years experience in healthcare. She is an inventor and holds multiple patents. Dr Bray works with multiple biotechnology and nutraceutical companies helping to develop the commercial and clinical development strategy. In the past she served as a Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline and also as Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc, USA and as Principal Clinical Research Scientist at Antivirals, Glaxo Wellcome, UK and USA. Dr Bray has extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and emerging markets. She is the European Commission's Scientific Expert and acts as a business advisor to investment companies in USA and Europe.


Since 2012 Dr Bray has been involved in helping companies, research institutions and governments to establish legal hemp and cannabis programs, from industrial applications like fiber production and building materials, fuels and plastics to developing novel formulations for pure compounds and crude extracts to deliver precise oral dosing of cannabinoids in the multiple therapeutic applications.


In addition to her industrial activities she served as a Member of the Scientific Staff and the Head of Scientific Business Development of The UK Medical Research Council Clinical Trials Unit, currently holds an honorary Senior Lecturer position at the University of London and serves as a reviewer for a number of scientific journals.


Specialties: Business development, pre-clinical and clinical strategy to develop novel pharmaceuticals, nutraceuticals and functional food products, solutions for conditions related to aging, including inflammation.